ProCE Banner Activity

Phase I/II Trial: Weekly Carfilzomib, Pomalidomide, and Dexamethasone in R/R Multiple Myeloma

Slideset Download
Conference Coverage
Weekly carfilzomib with pomalidomide and low-dose dexamethasone appears effective with better tolerability in relapsed/refractory MM.

Released: December 07, 2016

Expiration: December 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen